Product Details
| Product Name:
Inflachromene |
CAS No.:
908568-01-4 |
| Purity:
99.88% |
Supply Ability:
10g |
| Release date:
2024/11/20 |
Product Introduction
Bioactivity
| Name | Inflachromene |
| Description | Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene reduces seizure severity in a mouse model of epilepsy by inhibiting HMGB1 translocation, inhibits endothelial proliferation through the HMGB1/2-regulated TLR4-NF-κB pathway, and inhibits autophagy by regulating Beclin 1 activity. Inflachromene can be used to study epilepsy. |
| In vitro | In BV-2 microglial cells, Inflachromene efficiently blocks LPS-induced nitrite release in a dose-dependent manner (0.01-100 μM; 24 h) without any toxicity[1].
After LPS stimulation, Inflachromene (1-10 μM) suppresses the increased levels of inflammation-related genes, such as Il6, Il1b, Nos2, and Tnf[1].
At a concentration of 5 μM, Inflachromene reduces LPS-induced secretion of the proinflammatory cytokine TNF-α[1].
In microglia, Inflachromene (5 μM; 30 min) substantially suppresses the nuclear translocation of NF-κB and the degradation of IκB[1].
The phosphorylation of ERK, JNK, and p38 MAPK in microglia induced by LPS is inhibited by Inflachromene (1-10 μM; 30 min)[1].
In the co-culture of neuroblastoma and primary neuronal cells, Inflachromene (10 μM; 30 min) completely prevents the death by inhibiting microglia-mediated neurotoxicity[1].There is no significant effect on the viability of neurons with Inflachromene (1-10 μM; 24 h)[1]. |
| In vivo | In a dose-dependent manner (2-10 mg/kg; i.p. once daily for 4 days), Inflachromene effectively blocks LPS-mediated microglial activation[1].
For a duration of 30 days (10 mg/kg; i.p. once daily), Inflachromene significantly reduces the progression of disease, as determined by EAE clinical score[1].
When administered intravenously (i.v.) at a dose of 1 mg/kg, Inflachromene exhibits a long half-life (14.1±6.43 h) and moderate Vss (2.02±1.02 L/kg)[2].
Given orally (p.o.) at a dose of 1 mg/kg, Inflachromene shows high oral bioavailability (94%) and Cmax (0.59±0.16 g/mL)[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 80 mg/mL (211.98 mM), Sonication is recommended.
|
| Keywords | Inflachromene |
| Related Compound Libraries | Bioactive Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:186495-99-8
$293.00 / 1mg
-
CAS:91595-86-7
$293.00 / 1mg
-
CAS:2089035-40-3
$293.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States